• 1
    Glimerius B, Hoffman K, Haglund U, Nyren O, Sjoden PO. Initial or delayed chemotherapy with best supportive therapy in advanced gastric cancer. Ann Oncol 1994; 5: 18990.
  • 2
    Pyrhonen S, Kuitunen T, Nyandoto P, Kouri M. Randomized comparison of fluorouracil, epidoxorubicin and methotrexate (FEMTX) plus supportive care with supportive care alone in patients with non-resectable gastric cancer. Br J Cancer 1995; 71: 58791.
  • 3
    Glimerius B, Ekstrom K, Hoffman K, Graf W, Sjoden PO, Haglund U, Svensson C, Enander LK, Linne T, Sellstrom H, Heuman R. Randomized comparison between chemotherapy plus best supportive care with best supportive care in advanced gastric cancer. Ann Oncol 1997; 8: 1638.
  • 4
    Herskovic A, Martz K, Sarraf AM, Leichman L, Brindle J, Brindle J, Vaitkevicius V, Cooper J, Byhardt R, Davis L, Emami B. Combined chemotherapy and radiotherapy compared with radiotherapy alone in patients with cancer of the esophagus. N Engl J Med 1992; 326: 15938.
  • 5
    Vanhoefer U, Rougier P, Wilke H, Ducreux MP, Lacave AJ, Custem VE, Planker M, Santos JG, Piedbois P, Paillot B, Bodenstein H, Schmoll HJ, et al. Final results of a randomized phase III trial of sequential high-dose methotrexate, fluorouracil, and doxorubicin versus etoposide, leucovorin, and fluorouracil versus infusional fluorouracil and cisplatin in advanced gastric cancer: a trial of the European Organization for Research and Treatment of Cancer Gastrointestinal Tract Cancer Cooperative Group. J Clin Oncol 2000; 18: 264857.
  • 6
    Maughan TS, James RD, Kerr DJ, Ledermann JA, Seymour MT, Topham C, McArdle C, Cain D, Stephens RJ, Medical Research Council Colorectal Cancer Group. Comparison of survival, palliation, and quality of life with three chemotherapy regimens in metastatic colorectal cancer: a multicentre randomized trial. Lancet 2002; 359: 155563.
  • 7
    Early Breast Cancer Trialists' Collaborabive Group (EBCTCG). Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials. Lancet 2005; 365: 1687717.
  • 8
    Gibson MK, Li Y, Murphy MH, DeConti RC, Ensley J, Forastiere AA, Eastern Cooperative Oncology Group. Randomized phase III evaluation of cisplatin plus fluorouracil versus cisplatin plus paclitaxel in advanced head and neck cancer (E1395): an intergroup trial of the Eastern Cooperative Oncology Group. J Clin Oncol 2005; 23: 35627.
  • 9
    Langenbach RJ, Danenberg PV, Heidelgerger C. Thymidylate synthase: mechanism of inhibition by 5-fluoro-2[prime]-deoxyuridylate. Biophys Res Commun 1972; 48: 156571.
  • 10
    Peters GJ, Wilt CL, Triest B, Pisanelli CG, Johnston PG, Groeningen CJ, Pinedo HM. Thymidylate synthase and drug resistance. Eur J Cancer 1995; 31A: 1299305.
  • 11
    Fukushima M, Okabe H, Fujioka A, Nakano K, Ohshimoto H, Takeda S, Shirasaka T. Preclinical antitumor efficacy of S-1: a new oral formulation of 5-fluorouracil on human tumor xenografts. Int J Oncol 1998; 13: 6938.
  • 12
    Sugimachi K, Maehara Y, Horikoshi N, Shimada Y, Sakata Y, Taguchi T. The S-1 gastrointestinal cancer study group: an early phase II study of oral S-1, a newly developed 5-fluorouracil derivative for advanced and recurrent gastrointestinal cancers. Oncology 1998; 57: 20210.
  • 13
    Sakata Y, Ohtsu A, Horikoshi N, Sugimachi K, Mitachi Y, Taguchi T. Late phase II study of novel oral fluoropyrimidine anticancer drug S-1 (1M tegafur-0.4M Gimestat-1M otastat potasium) in advanced gastric cancer patients. Eur J Cancer 1998; 34: 171520.
  • 14
    Hirata K, Horikoshi N, Aiba K, Okazaki M, Denno R, Sasaki K, Nakano Y, Ishizaka H, Yamada Y, Uno S, Taguchi T, Shirasaka T. Pharmakokinetic study of S-1, a novel oral fluorouracil antitumor drug. Clin Cancer Res 1999; 5: 20005.
  • 15
    Koizumi W, Kurihara M, Nakano S, Hasegawa K. The S-1 gastrointestinal cancer study group: phase II study of S-1, a novel derivative 5-fluorouracil, in advanced gastric cancer. Oncology 2000; 58: 1917.
  • 16
    Maehara Y. S-1 in gastric cancer: a comprehensive review. Gastric Cancer 2003; 6 ( Suppl 1): 28.
  • 17
    Shirasaka T, Nakano K, Takechi T, Satake H, Uchida J, Fujioka A, Saito H, Oyama K, Takeda S, Unemi N, Fukushima M. Antitumor activity of 1M tegafur-0.4M 5-chloro-2,4-dihydroxypyrimidine-1M potasium oxonate (S-1) against human colon carcinoma orthotopically implanted into nude rats. Cancer Res 1996; 56: 26026.
  • 18
    Ringel I, Horwitz B. Studies with RP56976 (Taxotere): a semisynthetic analogue of taxol. J Natl Cancer Inst 1991; 83: 28891.
  • 19
    Kelland LR, Abel G. Comparative in vitro cytotoxicity of taxol and Taxotere against cicplatin-sensitive and -resistant human ovarian carcinoma cell lines. Cancer Chemother Pharmacol 1992; 30: 44450.
  • 20
    Bissery MC, Nohynek G, Sanderink GJ, Lavelle F. Docetaxel (Taxotere): a review of preclinical and clinical experience. Anticancer Drugs 1995; 6: 33968.
  • 21
    Bang YJ, Kang WK, Kang YK, Kim HC, Jacques C, Zuber E, Daglish B, Boudraa Y, Kim WS, Heo DS, Kim NK. Docetaxel 75 mg/m2 is active and well tolerated in patients with metastatic or recurrent gastric cancer: a phase II trial. Jpn J Clin Oncol 2002; 32: 24854.
  • 22
    Kaori F, Yutaka T, Takeshi T. Schedule dependency of antitumor activity in combination therapy with capecitabine/5′-deoxy-5-fluorouridine and docetaxel in breast cancer models. Clin Cancer Res 2001; 7: 107986.
  • 23
    Muro K, Hamaguchi T, Ohtsu A, Boku N, Chin K, Hyodo I, Fujita H, Takiyama W, Ohtsu T. A phase II study of single-agent docetaxel in patients with metastatic esophageal cancer. Ann Oncol 2004; 15: 9559.
  • 24
    Genet D, Cupissol D, Calais G, Bontemps P, Bourgeois H, Dutin JP, Philippi MH, Bendahmane B, Mallard CM, Tubiana MN. Docetaxel plus 5-fluorouracil in locally recurrent and/or metastatic squamous cell carcinoma of the head and neck: a phase II multicenter study. Am J Clin Oncol 2004; 27: 4726.
  • 25
    Yoshida K, Toge T, Minomiya M, Takakura N, Hirabayashi N, Takiyama W, Sato Y, Terashima M, Goto M, Sakamoto J, Nishiyama M. Phase II study of S-1 and docetaxel combination in advanced or recurrent gastric cancer. ASCO 2005 4049 (abstract).
  • 26
    Yoshida K, Hirabayashi N, Takiyama W, Ninomiya M, Takakura N, Sakamoto J, Nishiyama M, Toge T. Phase I study of combination therapy with S-1 and Docetaxel (TXT) for advanced or recurrent gastric cancer. Anticancer Res 2004; 24: 194351.
  • 27
    Spears CP, Shahinian AH, Moran RG, Heidelbelger C, Corbett TH. In vivo kinetics of thymidylate synthetase inhibition of 5-fluorouracil-sensitive and -resistant murine colon adenocarcinomas. Cancer Res 1982; 42: 4506.
  • 28
    Yamada H, Fukushima M, Koizumi K, Katahara H, Nakanishi H, Teshima S, Kamiyama Y, Ikenaka K. Regulation of dihydropyrimidine dehydrogenase gene expression in regenerating mouse liver. Int J Oncol 2003; 22: 35964.
  • 29
    Unemi N, Takeda S, Tajima K, Kawaguchi Y, Yasuda A. Effect of coadministration of uracil on the antitumor activity of 1-(Terahydro-2-furanyl)-5-fluorouracil and the level of 5-fluorouracil in AH 130 bearing Rats. Chemotherapy 1981; 29: 16475.
  • 30
    Koizumi W, Tanabe S, Saigenji K, Ohtsu A, Boku N, Nagashima F, Shirao K, Matsumura Y, Gotoh M. Phase I/II study of S-1 combined with cisplatin in patients with advanced gastric cancer. Br J Cancer 2003; 89: 220712.
  • 31
    Ichikawa W, Takahashi T, Suto K, Yamashita T, Nihei Z, Shirota Y, Shimizu M, Sasaki Y, Hirayama R. Thymidylate synthase predictive power is overcome by irinotecan combination therapy with S-1 for gastric cancer. Br J Cancer 2004; 1: 16.
  • 32
    Etienne MC, Cheradame S, Fischel JL, Formento P, Dassonville O, Renee N, Schneider M, Thyss A, Demard F, Milano G. Response to fluorouracil therapy in cancer patients: the role of tumoral dihydropyrimidine dehydrogenase activity. J Clin Oncol 1995; 13: 166370.
  • 33
    McLeod HL, Sludden J, Murray GI, Keenan RA, Davidson AI, Park K, Koruth M, Cassidy J. Characterization of dihydropyrimidine dehydrogenase in human colorectal tumors. Br J Cancer 1998; 77: 4615.
  • 34
    Beck A, Etienne MC, Cheradame S, Fischel JL, Formento P, Renee N. A role for dihydropyrimidine dehydrogenase and thymidylate synthase in tumor sensitivity to fluorouracil. Eur J Cancer 1994; 30A: 151722.
  • 35
    Lenz HJ, Leichman CG, Danenberg KD, Danenberg PV, Groshen S, Cohen H, Laine L, Crookes P, Silbermann H, Baranda J, Garcia Y, Li J, et al. Thymidylate synthase mRNA level in adenocarcinoma of the stomach: a predictor for primary tumor response and overall survival. J Clin Oncol 1995; 14: 17682.
  • 36
    Yoshinare K, Kubota T, Watanabe M, Wada N, Nishibori H, Hasegawa H, Kitajima M, Takachi T, Fukushima M. Gene expression in colorectal cancer and in vitro chemosensitibity to 5-fluorouracil: a study of 88 surbical specimens. Cancer Sci 2003; 94: 6338.
  • 37
    Ichikawa W, Uetake H, Shirota Y, Yamada H, Nishi N, Nihei Z, Sugihara K, Hirayama R. Combination of dihydropyrimidine dehydrogenase and thymidylate synthase gene expressions in primary tumors as predictive parameters for the efficacy of fluoropyrimidine-based chemotherapy for metastatic colorectal cancer. Clin Cancer Res 2003; 9: 78691.
  • 38
    Salonga D, Danenberg DK, Johnson M, Metzger R, Groshen S, Tsao-Wei DD, Lenz HJ, Leichman CG, Leichman L, Diasio RB, Danenberg PV. Colorectal tumors responding to 5-fluorouracil have low gene expression levels of dihydropyrimidine dehydrogenase, thymidylate synthase, and thymidine phosphorylase. Clin Cancer Res 2000; 6: 13227.
  • 39
    Ishikawa Y, Kubota T, Otani Y, Watanabe M, Teramoto T, Kumai K, Kitajima M, Takechi T, Okabe H, Fukushima M. Dihydropyrimidine dehydrogenase activity and messenger RNA level may be related to the antitumor effect of 5-fluorouracil, in advanced gastric cancer. For the S-1 cooperative Gastric Cancer Study Group. Oncology 1999; 8: 1917.
  • 40
    Triest VB, Pinedo HM, Giaccone G, Peters GJ. Downstream molecular determinants of response to 5-fluorouracil and antifolate thymidylate synthase inhibitors. Ann Oncol 2000; 11: 38591.
  • 41
    Boku N, Chin K, Hosokawa K, Ohtsu A, Tajiri H, Yoshida S, Yamao T, Kondo H, Shirao K, Shimada Y, Saito D, Hasebe T, et al. Biological markers as a predictor for response and prognosis of unresectable gastric cancer patients treated with 5-fluorouracil and cis-platinum. Clin Cancer Res 1998; 4: 146974.
  • 42
    Yeh KH, Shun CT, Chen CL, Lin JT, Lee WJ, Lee PH, Chen YC, Cheng AL. High expression of thymidylate synthase is associated with the drug resistance of gastric carcinoma to high dose 5-fluorouracil-based systemic chemotherapy. Cancer 1998; 82: 162631.
  • 43
    Kornmann M, Schwabe W, Sander S, Kron M, Straeter J, Polat S, Kettner E, Weiser KH, Baumann W, Schramm H, Haeusler P, Ott K, et al. Thymidylate synthase and dihydropyrimidine dehydrogenase mRNA expression levels: predictors for survival in colorectal cancer patients receiving adjuvant 5-fluorouracil. Clin Cancer Res 2003; 9: 411624.
  • 44
    Nishiyama M, Yamamoto W, Park JS, Okamoto R, Hanaoka H, Takano H, Saito N, Matsukawa M, Shirasaka T, Kurihara M. Low-dose cisplatin and 5-fluorouracil in combination can repress increased gene expression of cellular resistance determinants to themselves. Clin Cancer Res 1999; 5: 26208.
  • 45
    Chu E, Koeller DM, Casey JL, Drake JC, Chabner BA, Elwood PC, Zinn S, Allegra CJ. Autoregulation of human thymidylate synthase messenger RNA translation by thymidylate synthase. Proc Natl Acad Sci USA 1991; 88: 897781.
  • 46
    Farrugia DC, Ford ER, Cunningham D, Danenberg KD, Danenberg PV, Aherne GW, Hardcastle A, McCarthy K, Jackman AL. Thymidylate synthase expression in advanced colorectal cancer predicts for response to Raltirexed. Clin Cancer Res 2003; 9: 792801.
  • 47
    Pullarkat S, Ghaderi V, Ingles S, Xiong Y, Chen P, Stoelmacher J, Gupta M, Tsao-Wei D, Groshen S, Lenz HJ. Human thymidylate synthase gene polymorphism determines response to 5-FU chemotherapy. Proc Am Soc Clin Oncol 2000; 19: 243a.
  • 48
    Ukon K, Tanimoto K, Shimokuni T, Noguchi T, Hiyama K, Tsujimoto H, Fukushima M, Toge T, Nishiyama M. Activator protein accelerates dihydropyrimidine dehydrogenase gene transcription in cancer cells. Cancer Res 2005; 65: 105562.
  • 49
    Noguchi T, Tanimoto K, Shimokuni T, Ukon K, Tsujimoto H, Fukushima M, Noguchi T, Kawahara K, Hiyama K, Nishiyama M. Aberrant methylation of DPYD promoter, DPYD expression, and cellular sensitivity to 5-fluorouracil in cancer cells. Clin Cancer Res 2004; 10: 71007.
  • 50
    Issi K, Sakuyama T, Gen T, Nakamura Y, Kuroda T, Katuyama T, Maekawa Y. Predicting 5-FU sensitivity using human colorectal cancer specimen: comparison of tumor dihydropyrimidine dehydrogenase and orotate phosphoribosyl transferase activities with in vitro chomosensitivity to 5-FU. Int J Clin Oncol 2002; 7: 33542.
  • 51
    Fujii R, Seshimo A, Kameoka S. Relationships between the expression of thymidylate synthase, dihydropyrimidine dehydrogenase, and orotate phosphoribosyltransferase and cell proliferative activity and 5-fluorouracil sensitivity in colorectal carcinoma. Int J Clin Oncol 2003; 8: 728.
  • 52
    Ichikawa W, Uetake H, Shirota Y, Yamada H, Takahashi T, Nihei Z, Sugihara K, Sasaki Y, Hirayama R. Both gene expression for orotate phosphoribosyltransferase and its ratio to dihydropyrimidine dehydrogenase influence outcome following fluoropyrimidine-based chemotherapy for metastatic colorectal cancer. Br J Cancer 2003; 89: 148692.
  • 53
    Nozawa H, Tsukui H, Nishida K, Yakumaru K, Nagawa H, Sekikawa T. Dihydropyrimidine dehydrogenase expression in preoperative biopsy and surgically resected specimens of gastric carcinoma. Cancer Chemother Pharmacol 2002; 49: 26774.